{
  "source": "PA-Med-Nec-Vyleesi.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2178-5\nProgram Prior Authorization/Medical Necessity\nMedication Vyleesi™ (bremelanotide)\nP&T Approval Date 11/2019, 8/2021, 9/2022, 11/2023, 11/2024\nEffective Date 2/1/2025\n1. Background:\nVyleesi is indicated for the treatment of premenopausal women with acquired, generalized\nhypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes\nmarked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric\ncondition, problems within the relationship, or the effects of a medication or other drug substance.\nAcquired HSDD refers to HSDD that develops in a patient who previously had no problems with\nsexual desire. Generalized HSDD refers to HSDD that occurs regardless of the type of stimulation,\nsituation or partner. Vyleesi is not indicated for the treatment of HSDD in postmenopausal women\nor in men and is not indicated to enhance sexual performance.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Vyleesi will be approved based on all of the following criteria:\na. Diagnosis of one of the following:\n(1) Acquired, generalized hypoactive sexual desire disorder (HSDD)\n-OR-\n(2) Female sexual interest/arousal disorder\n-AND-\nb. Symptoms of HSDD or female sexual interest/arousal disorder have persisted for at\nleast 6 months\n-AND-\nc. Low sexual desire is NOT due to any of the following:\n(1) A co-existing medical or psychiatric condition\n(2) Problems within the relationship\n(3) The effects of a medication or other drug substance\n-AND-\nd. Patient was female at birth\n© 2024 UnitedHealthcare Services Inc.\n1\n-AND-\ne. Patient is premenopausal\n-AND-\nf. Patient does not have uncontrolled hypertension\n-AND-\ng. Patient does not have known cardiovascular disease\nInitial authorization will be issued for 2 months\nB. Reauthorization\n1. Vyleesi will be approved based on all of the following criteria:\na. Documentation of positive clinical response to Vyleesi t",
    "ase\nInitial authorization will be issued for 2 months\nB. Reauthorization\n1. Vyleesi will be approved based on all of the following criteria:\na. Documentation of positive clinical response to Vyleesi therapy\n-AND-\nb. Patient continues to be premenopausal\nReauthorization will be issued for 12 months\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Supply limits may be in place\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n4. References:\n1. Vyleesi [package insert]. Cranbury, NJ: Palatin Technologies; February 2021.\n2. Sexual dysfunctions. In: Diagnostic and Statistical Manual of Mental Disorders, 5th ed.,\nAmerican Psychiatric Association, Arlington, Virginia 2013.\n3. Overview of Sexual dysfunction in females: Management. UpToDate. Updated February 1, 2023.\nLast accessed October 4, 2024.\nProgram Prior Authorization/Medical Necessity – Vyleesi\nChange Control\nDate Change\n11/2019 New program.\n© 2024 UnitedHealthcare Services Inc.\n2\n8/2021 Updated references.\n9/2022 Updated references.\n11/2023 Updated references.\n11/2024 Annual review. Updated references.\n© 2024 UnitedHealthcare Services Inc.\n3"
  ]
}